vs
Side-by-side financial comparison of Alkermes plc. (ALKS) and UNITED THERAPEUTICS Corp (UTHR). Click either name above to swap in a different company.
UNITED THERAPEUTICS Corp is the larger business by last-quarter revenue ($790.2M vs $384.5M, roughly 2.1× Alkermes plc.). UNITED THERAPEUTICS Corp runs the higher net margin — 46.1% vs 12.8%, a 33.3% gap on every dollar of revenue. On growth, UNITED THERAPEUTICS Corp posted the faster year-over-year revenue change (7.4% vs -10.6%). UNITED THERAPEUTICS Corp produced more free cash flow last quarter ($173.3M vs $170.0M). Over the past eight quarters, UNITED THERAPEUTICS Corp's revenue compounded faster (8.0% CAGR vs 4.8%).
Alkermes plc is a fully-integrated biopharmaceutical company that focuses on developing medicines for psychiatric and neurological disorders. The company was founded in 1987 by Michael Wall. In September 2011 Alkermes, Inc. merged with Elan Drug Technologies (EDT), the former drug formulation and manufacturing division of Élan Corporation, plc. The company is headquartered in Dublin, and has an R&D center in Waltham, Massachusetts, and a manufacturing facility in Wilmington, Ohio.
United Therapeutics Corporation is an American biotechnology company that develops pharmaceuticals and technologies related to organ transplantation, including xenotransplantation. Many of the company's products are focused towards lung disease and organ manufacturing. United Therapeutics is co-headquartered in Silver Spring, Maryland and Research Triangle Park, North Carolina, with additional facilities in Magog and Bromont, Quebec; Melbourne and Jacksonville, Florida; Blacksburg, Virginia; ...
ALKS vs UTHR — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $384.5M | $790.2M |
| Net Profit | $49.3M | $364.3M |
| Gross Margin | 88.0% | 86.9% |
| Operating Margin | 15.1% | 45.1% |
| Net Margin | 12.8% | 46.1% |
| Revenue YoY | -10.6% | 7.4% |
| Net Profit YoY | -66.3% | 20.9% |
| EPS (diluted) | $0.29 | $7.66 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $384.5M | $790.2M | ||
| Q3 25 | $394.2M | $799.5M | ||
| Q2 25 | $390.7M | $798.6M | ||
| Q1 25 | $306.5M | $794.4M | ||
| Q4 24 | $430.0M | $735.9M | ||
| Q3 24 | $378.1M | $748.9M | ||
| Q2 24 | $399.1M | $714.9M | ||
| Q1 24 | $350.4M | $677.7M |
| Q4 25 | $49.3M | $364.3M | ||
| Q3 25 | $82.8M | $338.7M | ||
| Q2 25 | $87.1M | $309.5M | ||
| Q1 25 | $22.5M | $322.2M | ||
| Q4 24 | $146.5M | $301.3M | ||
| Q3 24 | $92.4M | $309.1M | ||
| Q2 24 | $91.4M | $278.1M | ||
| Q1 24 | $36.8M | $306.6M |
| Q4 25 | 88.0% | 86.9% | ||
| Q3 25 | 86.9% | 87.4% | ||
| Q2 25 | 87.3% | 89.0% | ||
| Q1 25 | 83.9% | 88.4% | ||
| Q4 24 | 85.6% | 89.7% | ||
| Q3 24 | 83.3% | 88.9% | ||
| Q2 24 | 84.6% | 89.1% | ||
| Q1 24 | 83.3% | 89.2% |
| Q4 25 | 15.1% | 45.1% | ||
| Q3 25 | 22.6% | 48.6% | ||
| Q2 25 | 23.8% | 45.6% | ||
| Q1 25 | 4.5% | 48.2% | ||
| Q4 24 | 37.8% | 48.6% | ||
| Q3 24 | 27.7% | 45.8% | ||
| Q2 24 | 27.5% | 44.7% | ||
| Q1 24 | 12.4% | 52.6% |
| Q4 25 | 12.8% | 46.1% | ||
| Q3 25 | 21.0% | 42.4% | ||
| Q2 25 | 22.3% | 38.8% | ||
| Q1 25 | 7.3% | 40.6% | ||
| Q4 24 | 34.1% | 40.9% | ||
| Q3 24 | 24.4% | 41.3% | ||
| Q2 24 | 22.9% | 38.9% | ||
| Q1 24 | 10.5% | 45.2% |
| Q4 25 | $0.29 | $7.66 | ||
| Q3 25 | $0.49 | $7.16 | ||
| Q2 25 | $0.52 | $6.41 | ||
| Q1 25 | $0.13 | $6.63 | ||
| Q4 24 | $0.88 | $6.23 | ||
| Q3 24 | $0.55 | $6.39 | ||
| Q2 24 | $0.53 | $5.85 | ||
| Q1 24 | $0.21 | $6.17 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $388.6M | $2.9B |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.8B | $7.1B |
| Total Assets | $2.5B | $7.9B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $388.6M | $2.9B | ||
| Q3 25 | $616.4M | $2.8B | ||
| Q2 25 | $521.2M | $3.0B | ||
| Q1 25 | $399.8M | $3.3B | ||
| Q4 24 | $291.1M | $3.3B | ||
| Q3 24 | $396.3M | $3.3B | ||
| Q2 24 | $535.1M | $3.0B | ||
| Q1 24 | $420.8M | $2.7B |
| Q4 25 | $1.8B | $7.1B | ||
| Q3 25 | $1.7B | $6.6B | ||
| Q2 25 | $1.6B | $7.2B | ||
| Q1 25 | $1.5B | $6.8B | ||
| Q4 24 | $1.5B | $6.4B | ||
| Q3 24 | $1.3B | $6.1B | ||
| Q2 24 | $1.3B | $5.7B | ||
| Q1 24 | $1.3B | $5.3B |
| Q4 25 | $2.5B | $7.9B | ||
| Q3 25 | $2.3B | $7.4B | ||
| Q2 25 | $2.3B | $7.9B | ||
| Q1 25 | $2.1B | $7.7B | ||
| Q4 24 | $2.1B | $7.4B | ||
| Q3 24 | $2.2B | $7.1B | ||
| Q2 24 | $2.2B | $6.7B | ||
| Q1 24 | $2.1B | $6.5B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $170.1M | $346.2M |
| Free Cash FlowOCF − Capex | $170.0M | $173.3M |
| FCF MarginFCF / Revenue | 44.2% | 21.9% |
| Capex IntensityCapex / Revenue | 0.0% | 21.9% |
| Cash ConversionOCF / Net Profit | 3.45× | 0.95× |
| TTM Free Cash FlowTrailing 4 quarters | $480.3M | $1.0B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $170.1M | $346.2M | ||
| Q3 25 | $101.7M | $562.1M | ||
| Q2 25 | $150.2M | $191.7M | ||
| Q1 25 | $98.8M | $461.2M | ||
| Q4 24 | $190.4M | $341.2M | ||
| Q3 24 | $81.6M | $377.2M | ||
| Q2 24 | $146.0M | $232.2M | ||
| Q1 24 | $21.1M | $376.5M |
| Q4 25 | $170.0M | $173.3M | ||
| Q3 25 | $84.4M | $351.6M | ||
| Q2 25 | $137.2M | $129.5M | ||
| Q1 25 | $88.7M | $386.3M | ||
| Q4 24 | $180.6M | $254.5M | ||
| Q3 24 | $73.3M | $300.7M | ||
| Q2 24 | $138.9M | $187.1M | ||
| Q1 24 | $12.8M | $338.3M |
| Q4 25 | 44.2% | 21.9% | ||
| Q3 25 | 21.4% | 44.0% | ||
| Q2 25 | 35.1% | 16.2% | ||
| Q1 25 | 28.9% | 48.6% | ||
| Q4 24 | 42.0% | 34.6% | ||
| Q3 24 | 19.4% | 40.2% | ||
| Q2 24 | 34.8% | 26.2% | ||
| Q1 24 | 3.6% | 49.9% |
| Q4 25 | 0.0% | 21.9% | ||
| Q3 25 | 4.4% | 26.3% | ||
| Q2 25 | 3.3% | 7.8% | ||
| Q1 25 | 3.3% | 9.4% | ||
| Q4 24 | 2.3% | 11.8% | ||
| Q3 24 | 2.2% | 10.2% | ||
| Q2 24 | 1.8% | 6.3% | ||
| Q1 24 | 2.4% | 5.6% |
| Q4 25 | 3.45× | 0.95× | ||
| Q3 25 | 1.23× | 1.66× | ||
| Q2 25 | 1.72× | 0.62× | ||
| Q1 25 | 4.40× | 1.43× | ||
| Q4 24 | 1.30× | 1.13× | ||
| Q3 24 | 0.88× | 1.22× | ||
| Q2 24 | 1.60× | 0.83× | ||
| Q1 24 | 0.57× | 1.23× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ALKS
| Vivitrol | $124.1M | 32% |
| Aristada And Aristada Initio | $97.2M | 25% |
| LYBALVI | $94.1M | 24% |
| Royalty | $65.7M | 17% |
| Manufacturing Revenue | $3.3M | 1% |
UTHR
| Tyvaso DPI | $338.6M | 43% |
| Remodulin | $128.0M | 16% |
| Nebulized Tyvaso | $125.7M | 16% |
| Orenitram | $121.2M | 15% |
| Unituxin | $62.3M | 8% |
| Adcirca | $7.8M | 1% |
| Other | $6.6M | 1% |
